Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 12/20 | 0.40 |
| ▸ | ATR | Q13535 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016536 | 0.77 | ATM (0.35) | ATMATRPIK3CA | |
| SCHEMBL22017360 | 0.74 | KDM4E (0.43) | ATMNPC1GAARAB9AMAPK14 | |
| SCHEMBL24312294 | 0.71 | ADORA2B (0.40) | ATMADORA2BNPC1RXFP1 | |
| SCHEMBL22016877 | 0.70 | ADORA3 (0.41) | ADORA2BHPD | |
| SCHEMBL24390566 | 0.69 | ATM (0.41) | ATMATRPIK3CAMTORTRPC5 | |
| SCHEMBL24851463 | 0.67 | MAPK14 (0.41) | ATMATRADORA2BPIK3CAMTOR | |
| SCHEMBL24851745 | 0.67 | HSD17B10 (0.42) | ATMATRADORA2BMAPK14HPD | |
| SCHEMBL22017691 | 0.67 | GRM4 (0.44) | ATMATRADORA2BHPD | |
| SCHEMBL16352662 | 0.65 | ERCC1 (0.61) | ATMPOLBGAA | |
| SCHEMBL22016496 | 0.63 | PDE4B (0.41) | ATMATRADORA2BGAAPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ATM 2237/4885ATR 4499/4885ADORA2B 1152/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ATM 2237/4885ATR 4499/4885ADORA2B 1152/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | ATM 2237/4885ATR 4499/4885ADORA2B 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.